Molecular Partners AG
SIX:MOLN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.17
9.3
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Molecular Partners AG
Molecular Partners AG
Cash from Financing Activities
Molecular Partners AG
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Molecular Partners AG
SIX:MOLN
|
Cash from Financing Activities
-CHf1.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Cash from Financing Activities
$73.9m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Cash from Financing Activities
CHf40.1m
|
CAGR 3-Years
51%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Cash from Financing Activities
$354.1m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Cash from Financing Activities
-CHf53.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-67%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Cash from Financing Activities
CHf666k
|
CAGR 3-Years
-66%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
Molecular Partners AG
Glance View
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
See Also
What is Molecular Partners AG's Cash from Financing Activities?
Cash from Financing Activities
-1.2m
CHF
Based on the financial report for Jun 30, 2024, Molecular Partners AG's Cash from Financing Activities amounts to -1.2m CHF.
What is Molecular Partners AG's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-52%
Over the last year, the Cash from Financing Activities growth was 35%.
You don't have any saved screeners yet
